Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T18:26:49.545Z.
Consensus retrieved: 2026-10-06T12:08:08.708Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:26:49.545Z.
Quote observation: 2026-10-06T18:19:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bcc3f1894ec499320e43c54a24f2662d6ad9e54feca4b92c79248349e67b8166
Forward PE Ratio (N/A) = Dated Quote Price ($1.88) / Consensus Forward EPS ($-3.89)
FORWARD PE RATIO
N/A
GRI Bio, Inc.
Market Cap
$4.11M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| GRI Bio, Inc. (GRI) | $4.11M | N/A |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | N/A |
| 60 Degrees Pharmaceuticals, Inc. (SXTP)vs › | $4.01M | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.96M | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.30M | N/A |
| Evogene Ltd. (EVGN)vs › | $3.79M | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.43M | N/A |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.72M | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.51M | N/A |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.64M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.88, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.90 | $-4.29 – $-3.49 | 2 | n/m |
| 2027-12-31 | $-2.00 | $-3.79 – $-0.21 | 2 | n/m |
| 2028-12-31 | $-0.17 | $-0.17 – $-0.17 | 1 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
